Autres langues MEI Pharma, Inc. Börse Stuttgart

Actions

MMI0

US55279B3015

Temps Différé Börse Stuttgart Autres places de cotation 16:55:57 14/04/2023			Varia. 5j.	Varia. 1 janv.
4,272 ^EUR	+0,38 %		+1 961,78 %	+1 757,39 %

09/05	MEI Pharma, Inc. annonce ses résultats pour le troisième trimestre et les neuf mois terminés le 31 mars 2024	CI
11/04	MEI Pharma, Inc. annonce un plan stratégique visant à exploiter les récentes données cliniques positives sur le voruciclib et le ME-344	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)	14/05
MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights	09/05
MEI Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	09/05
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab in Relapsed Metastatic Colorectal Cancer Patients	12/04
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients	11/04
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344	11/04
MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data	11/04
MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients	11/04
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum	10/04
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia	26/03
MEI Pharma, Inc. Reports Update from Clinical Study Evaluating Oral Cdk9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia	26/03
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)	15/02
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights	13/02
MEI Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	13/02
MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024	16/01
MEI Pharma : Change in Certifying Accountants - Form 8-K	26/12
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)	14/12
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023	11/12
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib At ASH2023	11/12
Earnings Flash (MEIP) MEI PHARMA Posts Q1 Revenue $65.3M	09/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues MEI Pharma, Inc. Börse Stuttgart

Actions

MMI0

US55279B3015

Autres langues

Filtres